CIK 0002035832 · <br>Emerging growth company
Aktis Oncology, Inc.
Sign in to watch- Ticker
- AKTS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 852584233
- Phone
- 978-237-4380
- Business address
- 17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Chief Medical Officer sold 12,500 shares at an average $20.69 ($258,621)
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Director sold 4,856 shares at $24.56 ($119,274)
- 4 Open-market sale Director sold 3,065 shares at $25.21 ($77,259)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Operating Officer sold 50,000 shares at an average $27.75 ($1,387,558)
- 4 Open-market sale Chief Medical Officer sold 50,000 shares at an average $27.77 ($1,388,701)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
Page 1 of 4 · 70 filings